Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
|Sponsor Type||Funding Program Title||Amount and Duration||Description||Deadline|
|Tri-Agency||CIHR Operating Grant: Joint Programme on Neurodegenerative Disease Research (JPND) 2021||Up to CAD $111,000 per year for up to 3 years, for a total of CAD $333,000 per grant.||This is to establish ambitious, innovative, multi-disciplinary and multi-national collaborative research projects that aim to identify and measure physiological effects and related biomarkers that can be linked to the development of neurodegenerative diseases, as well as enhancing the understanding of causes underlying cellular, molecular, metabolic, inflammatory or other systemic processes. Proposals must focus on one or several of the following neurodegenerative diseases: Alzheimer's disease and other dementias; Parkinson's disease (PD) and PD-related disorders; Prion diseases; Motor neuron diseases; Huntington's disease; Spinocerebellar ataxia (SCA); Spinal muscular atrophy (SMA).|
For more information, please consult the JPND Call for Proposals.
|Pre-Proposal to JPND: March 2, 2021.
Full Proposal to JPND and CIHR Application: June 29, 2021.
|Tri-Agency||CIHR Project Grant Spring 2021||Project Grant funding levels are proportionate to the requirements of the research proposed, which is expected to vary by research field, research approach, and scope of proposal activities. Individual grant applications requesting a total of more than $13.75M from CIHR will be withdrawn.||The Project Grant program is designed to capture ideas with the greatest potential for important advances in fundamental or applied health-related knowledge, health care, health systems, and/or health outcomes by supporting projects or programs of research proposed and conducted by individual researchers or groups of researchers in all areas of health. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.|
Please select Unity Health Toronto as your institution.
NOTE: CIHR has made significant updates to the Spring 2021 Project Grant competition. Please see "What you should know about the Spring 2021 Project Grant competition" for further details.
|Registration: March 4, 2021
Application: April 1, 2021
|Tri-Agency||SSHRC Partnership Engage Grants||$7,000 to $25,000 for 1 year||Partnership Engage Grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. The small-scale, stakeholder-driven partnerships supported through the Partnership Engage Grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors.||March 15, June 15, September 15|
|Tri-Agency||Now Open: 13th JPIAMR Call - One Health interventions to prevent or reduce the development and transmission of AMR||Total estimated call budget is 24.9 million Euro. Projects 3 years maximum.||This call will specifically focus on tackling the rising threat of antibiotic resistance. Research proposals must focus on at least two out of the three "One-Health" settings, being: Human Health, Animal Health, and Environment. Proposals should aim to either:|
- Understand the impact of interventions on the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings; OR
- Design, implement, evaluate, and/or compare innovative interventions to control the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings.
Participation of low and middle income countries is encouraged.
NOTE: A live webinar for applicants will be held January 28, 2021. Registration is required. Please register here: https://invajo.com/l/IxlLhJbppQ
|Pre-proposal: March 16, 2021.
Application (by invitation): July 12, 2021.
|Tri-Agency||CIHR Chair: Applied Public Health||Up to $1,150,000.||The purpose of this funding opportunity is to fund mid-career (independent research position 5-15 years prior to the time of application) applied public health researchers in Canada who will undertake applied research programs that tackle pressing public health challenges and who will work with decision makers to help support evidence-informed decisions that improve health and health equity. CIHR anticipates funding 7 awards. |
Webinar: CIHR will host a webinar about this funding opportunity on Thursday, February 11, 2021 at 11:00 am ET. Registration is not required: Link.
NOTE: CRC holders cannot apply unless their CRC has concluded by December 15, 2021.
Letter of Intent: March 18, 2021.
Full Application (by invitation): September 2, 2021.
|Tri-Agency||Pre-Announcement: Human Frontier Science Program (HFSP) Research Grant Program||$265,000 for a team of 2; $365,000 for a team of 3; $465,000 for a team of 4 or more, for a period of 3 years.||HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries. Two types of Research Grants are available:|
- Research Grants - Program: For teams of independent researchers at any stage of their careers. Applications including independent investigators early in their careers are encouraged.
NOTE: Applications for applied research, including medical research typically funded by national medical research bodies such as CIHR, are not eligible.
|Initiation of Letter of Intent: March 18, 2021.
Letter of Intent: March 30, 2021.
Full Application (by invitation): mid-September, 2021.
|Tri-Agency||NSERC Idea to Innovation Grants (I2I Grants)||Market Assessment: up to 12 months, $15,000; Phase I: up to 12 months, $125,000; Phase Ib: up to 6 months, $60,000; Phase IIa: from 6 to 18 months, $125,000; Phase IIb: up to 24 months, $350,000||The objective of the Idea to Innovation (I2I) grants is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established Canadian company.||March 29, 2021; June 28, 2021; September 27, 2021.|
|Tri-Agency||CIHR Team Grant: Indirect Socio-Economic Burden of Inherited Diseases||The maximum amount per grant is $150,000 per year for up to 3 years, for a total of $450,000 per grant.||The specific objectives of this funding opportunity are to:|
- Determine the indirect socio and economic costs of patients living with inherited diseases;
- Identify the most notable indirect social costs of inherited disease and compare with those associated with common diseases;
- Determine impact of disease management on patients and families (e.g. hospital/clinic visits, special arrangements in houses to improve quality of life for patient).
For this call, inherited disease is defined as a disease that can be passed from one generation to the next and would include de novo mutations found in germline cells but would exclude 'rare' non-inheritable conditions (e.g. retinopathy of prematurity and most (but not all) childhood cancers).
|Registration: April 13, 2021.
Application: May 4, 2021.
|Tri-Agency||Pre-announcement: CIHR-Coalition for Epidemic Preparedness Innovations (CEPI) Leadership Award for Excellence in Vaccine Research for Infectious Diseases of Epidemic Potential||Maximum $100,000 from CIHR and minimum $100,000 from CEPI. Funding for up to 2 years.||This is for Canadian independent mid-career researchers to pursue a mutually beneficial research project that is co-developed with CEPI. This initiative advance research on CEPI's priority diseases and provide researchers with mentorship by CEPI, along with access to biological samples, innovative technologies, and new collaborative relationships with CEPI and their partners.|
Webinar: CIHR and CEPI will host a webinar about this funding opportunity on Thursday, March 4, 2021 at 1 pm ET. Details TBA.
NOTE: Applicant must be a mid-career researcher (i.e. at the time of application, has assumed their independent research position 5-15 years ago).
Deadline: April 20, 2021
|Tri-Agency||SickKids-CIHR Operating Grant: New Investigator Grants in Child and Youth Health (2021)||Up to $100,000 per year for up to 3 years.||This supports new investigators for research in biomedical, clinical, health systems and services, population and public health sectors that has the potential for significant impact on children's health outcomes. As of the application deadline, the applicant: |
- Is a principal investigator has not been awarded combined Operating Grant funding of $500,000 or more Canadian dollars.
- Is within six years (this has been updated from five years due to COVID-19) of their first academic appointment.
- Has at least 50% of protected research time for the duration of the project.
Visit the New Investigator Research Grants funding opportunity on the SickKids Foundation website for further details
|April 20, 2021|
|Tri-Agency||CIHR-Other: CIHR-CEPI Leadership Award for Vaccine Research||Maximum $100,000 from CIHR and minimum $100,000 from CEPI. Funding for up to 2 years.||This is for a mutually beneficial research project that mid-career researchers will co-develop with the Coalition for Epidemic Preparedness Innovations (CEPI). This funding opportunity focuses on the first part of CEPI's mission, i.e. to accelerate the development of vaccines against emerging infectious diseases.|
NOTE: Applicant must be a mid-career researcher (i.e. at the time of application, has assumed their independent research position 5-15 years ago).
|April 20, 2021
Webinar: CIHR and CEPI will host a webinar about this funding opportunity on Thursday, March 4, 2021 at 1 pm ET. Details TBA at CIHR's Webinars page.
|Tri-Agency||CIHR Training Grant: Health Research Training Platform (HRTP; 2021/22 Pilot)||Maximum amount per grant is $400,000 per year for up to 6 years, for a total of $2,400,000 per grant.||This is intended to support the development of interdisciplinary, inter-jurisdictional, and intersectoral research training platforms that will attract a diverse cadre of high-caliber trainees and ECRs, and equip them with the skills required for academic and non-academic careers. This funding opportunity will support training platforms relevant to the following research areas:|
- Boys, Men and Masculinities
- Digital Health Solutions for Seniors with Complex Health Needs
- Drug Safety and Effectiveness
- AI, Public Health and Equity
- Girls and Women's Health and Wellness
- Human Development, Child and Youth Health
- Improving Health Outcomes through Better Models of Care for Multimorbidity
- Integrating Mental Health Services within Primary and Community Care
- Nutrition, Metabolism and Diabetes
- Stigma Reduction and Life Course Mental Wellness for LGBTQ/2S Populations
- Vascular Cognitive Impairment
|Registration: April 21, 2021.
Application: June 22, 2021.
|Tri-Agency||CIHR Operating Grant: HIV/AIDS and STBBI Community-Based Research||Maximum $150,000 per year for up to 3 years for a total of $450,000 per grant.||The aim of the Operating Grant component of the CIHR HIV/AIDS and STBBI Community-Based Research (CBR) Program is to contribute to the creation, dissemination and use of health-related knowledge, and to help develop research capacity, by supporting original, high quality projects proposed and conducted in partnership between the community and academia.||April 27, 2021.|
|Tri-Agency||SSHRC Research Data Management Capacity Building Initiative Renewal||Events: $7,000 to $25,000 for 1 year; Outreach activities: $7,000 to $50,000 for 1 year||This initiative aims to continue helping the Canadian social sciences and humanities research community better understand data management, and incorporate data management considerations into research practices. The initiative will fund at least 10 meritorious Connection Grants proposals per competition for the November 2020, February, May and August 2021 cycles, to support the research community's development, adoption and dissemination of research data management standards, practices, tools and skills appropriate to their field.||May 1, 2021; August 1, 2021|
|Tri-Agency||SSHRC / Joint Initiative for Digital Citizen Research (IDCR) Connection Grants||Events: $7,000 to $25,000 for 1 year; Outreach activities: $7,000 to $50,000 for 1 year||The IDCR aims to develop a better understanding of the impacts of online disinformation in Canada, in order to better inform programs and policies, and to build Canada's capacity to conduct research on - and related to - countering online disinformation and other related online harms. This initiative will also help foster a community of researchers engaged with digital citizenship and online disinformation in Canada.||May 1, 2021; August 1, 2021|
|Tri-Agency||CIHR Team Grant: Diabetes Prevention and Treatment in Indigenous Communities: Resilience and Wellness||Letter of Intent stage: Development grants of up to $35,000 per grant.|
Full Application stage: Maximum $400,000 per year for up to 5 years, for a total of up to of $2,000,000 per grant.
|This supports Indigenous-led and community-driven research to define and integrate models of resilience and wellness into diabetes prevention and/or treatment approaches among First Nations, Inuit and Métis Peoples. This seeks applicants who are Indigenous community-based groups or non-governmental organizations, or individuals who self-identify as Indigenous (First Nations, Inuit or Métis) or provide evidence of having meaningful and culturally safe involvement with Indigenous Peoples.||Letter of Intent: May 26, 2021
Full Application: July 7, 2022
|Tri-Agency||CIHR Other: Hepatitis C Research||Up to $700,000 per year for up to 5 years for Research Area 1; up to $200,000 per year for up to 5 years for Research Area 2.||The Hepatitis C Research Initiative will primarily encourage a focus on hepatitis C prevention, testing and improved health outcomes for those living with hepatitis C; however, the successful applicants will be required to collaborate with other relevant research networks and teams. This opportunity will support a national collaborative research program relevant to the following two research areas: |
1 - Prevention of Hepatitis C and Reaching the Undiagnosed
2 - Long-Term Consequences and Cascade of Care
Webinar: CIHR plans to host webinar(s) to support participants with the requirements of the Hepatitis C Research opportunity. Links to follow at CIHR's Webinars page.
|June 1, 2021.|
|Tri-Agency||CIHR Team Grant: Indigenous Healthy Life Trajectories Initiative Cohort Research Study (I-HeLTI)||For the research grant, maximum $2,000,000 per year for up to 6 years. For the Collaborating Centre, maximum $350,000 per year for up to 6 years.||In 2019, three I-HeLTI research teams were funded to build the infrastructure and capacity needed to conduct an I-HeLTI Intervention Cohort Research Study. This funding opportunity will support the establishment of one I-HeLTI Intervention Cohort Research Study, as well as an I-HeLTI Collaborating Centre to support the activities of the cohort research study.|
NOTE: To be eligible, applicants must hold a Team Grant from the December 6, 2018, program launch of I-HeLTI where the funding start date of the grant was on November 1, 2019.
|June 9, 2021|
|Tri-Agency||CIHR Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C||Up to $100,000 per year for up to 1 year.||This funding opportunity will support projects across all pillars of research (biomedical research; clinical research; health services research; and social, cultural, environmental, and population health research) with a primary focus on STBBI of public health relevance including, but not limited to, chlamydia, gonorrhea, syphilis, hepatitis B and human papillomavirus (HPV). For any STBBI not listed above, applicants will be required to demonstrate the public health relevance of the disease-type being studied, and how it impacts the health of individuals nationally and globally.|
NOTE:Research projects focusing solely on HIV or hepatitis C will not be eligible for funding.
|June 9, 2021.|
|Tri-Agency||CIHR Team Grant: Indigenous Gender and Wellness Team Grant||Maximum $166,667 per year for up to 3 years, for a total of $500,000 per grant.||This will focus on addressing themes related to Indigenous gender and wellness. In this context, wellness should be broadly defined to encompass an Indigenous, holistic view of health. Projects can tie wellness to ceremony, language, culture, behaviours, land-based projects and more. Projects on topics important to Indigenous youth and young adults are especially encouraged.|
NOTE: Team Grants will not be restricted to those who received a Development Grant in Phase 2 of this initiative. However, at least one team member must have attended the Idea Fair and Learning Circle in June 2019.
|June 22, 2021.|
|Tri-Agency||NSERC Alliance Grants||$20,000 to $1 million per year for 1-5 years||Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.|
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Other Canadian||Canadian Orthopaedic Foundation CSES Research Grant||Up to $20,000 for 1-2 years.||This supports and encourages orthopaedic surgeons to conduct pre-clinical or clinical collaborative shoulder or elbow research study with the potential to improve the clinical outcomes of a shoulder or elbow disorder. One of the principal investigators must be a member of CSES in good standing. One of the Principal or Secondary Investigators must be a COA member or associate member in good standing.||February 28, 2021.|
|Other Canadian||U of T Temerty Innovation Grants for AI in Medicine||Up to $200,000 for 1 year.||The objectives are:|
- To identify promising high risk, high reward ideas that will transform healthcare over the next 20 years in AI in medicine.
- To encourage researchers to transcend boundaries by using diverse datasets and new technologies to improve care efficiency or patient outcomes.
- To stimulate the creation of a collaborative community focused on the innovation and implementation of AI in medicine.
NOTE: One of the Principal Investigators on an application must have a T-CAIREM affiliation.
|March 1, 2021.|
|Other Canadian||Kidney Foundation of Canada (KFOC): 2021 Competitions||--||The KFOC national research fund encourages research that advances current knowledge pertaining to the kidney, diseases of the kidney, organ donation and transplantation.||Allied Health Kidney Grants
Full Application Deadline: March 1, 2021.
|Other Canadian||Public Health Agency of Canada (PHAC) Immunization Partnership Fund: Increasing Confidence, Acceptance and Uptake of COVID-19 Vaccines||Minimum of $100,000 total to a maximum of $500,000. Minimum of 1 year duration; must be completed by March 31, 2023.||PHAC seeks letters of intent (LOI) for time-limited projects focussed on supporting health care providers to promote and counsel patients on vaccination, increasing Canadians' confidence in vaccines and addressing barriers to acceptance and uptake of COVID-19 vaccines. Projects funded through this program must support one of the following objectives:|
- Build capacity of health care providers (HCPs) as vaccinators and vaccination promoters
- Community-based COVID-19 education, promotion and outreach
- Build capacity for evidence-based vaccination communication
|LOI: March 5, 2021
Full Proposal: TBA upon invitation.
|Other Canadian||Ontario Institute for Regenerative Medicine (OIRM) KICK-START Innovation Investment Program||Targeted investment funding of up to $100,000.||This is designed to advance promising regenerative medicine (RM) technologies, attract early-stage investment and build valuable intellectual property (IP) in support of a company creation. As this is an investment program, each successful team will work with OIRM to set up a business structure that successfully promotes onward growth while generating value for the initial stakeholders, including the science team, the science institution and OIRM.||Notice of Intent: March 12, 2021.
Full Application: June 7, 2021.
|Other Canadian||Call for Applications: Women in Philanthropy for Providence (WIPP) / Men Advancing Philanthropy for Providence (MAPP) Innovation Funding||$60,000 (from WIPP) or $100,000 (from MAPP).||Once a year, WIPP and MAPP donors come together to vote on how their collective funding will be used to support the needs of Providence Healthcare. The Call for Applications is now open! Projects must be innovative and help patients, residents, or staff to flourish at Providence and at home. Projects must be led by 1) Providence clinical staff/physicians OR 2) a Unity Health appointed Researcher who is collaborating with Providence staff/physicians.|
If you have any questions about the application process, please reach out to Erica Conte in the Office of the VP, Research and Innovation at firstname.lastname@example.org. For a copy of the application form, please contact VPRI@smh.ca.
|March 12, 2021.|
|Other Canadian||Canadian Blood Services (CBS) Kenneth J. Fyke Award||Up to $100,000 for one year.||This supports health services and policy research in order to promote the development of evidence-based Canadian practices and policies in blood transfusion, blood stem cell transplantation, and organ and tissue transplantation for the benefit of Canadian patients.||March 19, 2021|
|Other Canadian||2021-23 Joint EMHSeed and XSeed Call for Proposals||$60,000 per year for 2 years.|
NOTE: This grant requires matching funding. Please contact VPRI@smh.ca as soon as possible if you intend to apply.
|This promotes multi-disciplinary research and catalyze new innovative partnerships between a coPI from the Faculty of Applied Science and Engineering (FASE) and a coPI from outside Engineering. One PI should have a primary appointment with an Engineering unit, and one PI should have his/her primary appointment outside Engineering. Partner divisions for these programs are:|
- For EMHSeed: Temerty Faculty of Medicine (FoM), UofT Affiliated Hospitals, Medicine by Design (MbD), Translational Biology and Engineering Program (TBEP)
- For XSeed: Faculty of Arts and Science (FAS), University of Toronto Mississauga (UTM), University of Toronto Scarborough (UTSC), Dalla Lana School of Public Health (DLSPH), as well as other UofT Divisions.
Information session:An information session will be held on February 25th from 2:30-3:30pm to explain the program and answer your questions. To join the session, please click on the MSTeams link: Click here to join the meeting. Or call in (audio only):+1 647-794-1609 Phone Conference ID: 197 873 233#.
|March 31, 2021.|
|Other Canadian||SSHRC Connection Grants: OVPI matching funds opportunity for U of T applicants- Update||$5,000 in matching funds to an applicants CG application.||The University of Toronto Office of the Vice President, International (OVPI) will support U of T applicants for the SSHRC Connection Grants (CG). To be eligible, CG proposals must have a significant international component (for example, main presenters/participants at a proposed CG event must be U of T researchers, but co-applicants/collaborators are required to be from an international institution, with presenters from outside of Canada).|
For more information, please contact Anett Trifonov, Research Officer, International, email@example.com
|May 2021 CG competition: April 13, 2021.|
|Other Canadian||Connaught Global Challenge Research Program||Up to $250,000 for 1 year. For proposals with an international partner and international training component, $250,000 for 1 year plus an additional $150,000 and 3 years for the training component.||This supports new collaborations with U of T researchers and students from multiple disciplines, along with innovators and thought leaders from other sectors. A supplementary stream of funding through the Connaught Global Research Impact Program (C-GRIP) provides additional funding for teams who wish to partner internationally. The additional funding will support global mobility and exchange for graduate students and postdoctoral fellows. It is open to all U of T full-time professorial staff (tenured or tenured stream).||April 19, 2021.|
|Other Canadian||Canadian Donation and Transplantation Research Program (CDTRP) Research Innovation Grant Competition 2021||$30,000 for 18-24 months.||This supports pilot research projects that align with CDTRP's One-Transplant-for-Life vision, which is to fulfill every donor opportunity and turn transplant into a cure. These projects must be new stand-alone studies that align with one of the 5 Themes of the CDTRP and should be used to generate preliminary data to support further investigation. The 5 CDTRP Themes are:|
1. Create a culture of donation
2. Inform universal practices for donation
3. Engineer and allocate a better graft
4. Tailor an optimal immune system for each patient
5. Restore long-term health
|May 3, 2021.|
|Other Canadian||Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs||--||The NRC offers potential opportunities for collaboration in the following areas:|
- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
|Other Canadian||Government of Canada: CanExport for Innovators||Maximum of $75,000||Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.|
Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
|Other Canadian||Weston Brain Institute: Early Phase Clinical Trials: Canada||Up to $1,500,000 per project for up to 4 years||Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.||Rolling deadline
|Other Canadian||Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant||Health Research Grant: Up to $250,000 for 3 years.|
New Investigator Grant: Up to $300,000 for 3 years.
|Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment.||Rolling deadline|
|Other Canadian||Telus Funds||Various||For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.||Various
|Other Canadian||Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program||Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)||This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).|
If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to).
|Other Canadian||Mitacs Accelerate Graduate Student Internships||$15,000 award (with at least $10,000 to support the student stipend and the balance available for project resources)||The Mitacs Accelerate program helps fund partnered research projects by supporting Masters, PhD students, or postdoctoral fellows through "units" consisting of 4-month paid graduate student internships.||No Deadline|
|International||Pfizer Global Medical Grants (GMG): Request for Proposals (RFP) 2021 Global Hemophilia ASPIRE- Various Opportunities||Basic science projects: Up to USD $90,000 per year for 1-2 years.|
Clinical science projects: Up to USD $70,000 per year for 1-2 years.
Young Investigator basic or clinical project: Up to USD $70,000 per year for 1-2 years.
|Projects that will be considered for Pfizer support will focus on the following areas: 1) Basic and Clinical Science of Gene Therapy for Hemophilia; 2) Basic and Clinical Science of Tissue Factor Pathway Inhibitor (TFPI) and anti-TFPI monoclonal antibodies; 3) Burden of disease: Clinical Hemophilia A and B.|
NOTE: For the Young Investigator award, the PI must have received their most recent degree within the last 7 years.
|March 1, 2021.|
|International||Society for Vascular Surgery (SVS) Foundation Clinical Research Seed Grants||USD $25,000 for 1 year.||This supports clinical investigation in vascular disease, preferably patient-oriented: research conducted with human subjects or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator directly interacts with human subjects. Small-scale clinical trials and ancillary studies in the setting of existing clinical trials (industry or NIH-supported) will be accepted. The PI must be 1) an SVS Active Member within the first 10 years of practice or 2) a fellowship- or integrated residency-trained, board-eligible, vascular surgeon within the first 10 years of practice with a full-time faculty position with an SVS Active Member serving as mentor.||March 1, 2021.|
|International||Vascular Cures Wylie Scholar Program||USD $150,000 for 3 years.||This provides a career development grant to outstanding young vascular surgeon-scientists who combine active patient care with academic research. The award may be used to support research in the following areas: basic science, translational, clinical research, outcomes/health services research, teaching, community service, and patient care. The candidate must be within 5 years of their first faculty appointment at the time of application.|
NOTE: Only one nomination per institution per year will be considered. Please see opportunity for additional criteria that must be met.
|March 1, 2021.|
|International||Craig H. Neilsen Foundation: Various Opportunities||Psychosocial Research:|
Pilot Grants: Up to USD $200,000 for 2 years;
Studies and Demonstration Projects: Up to USD $400,000 for 3 years.
Spinal Cord Injury Research on the Translational Spectrum:
Pilot Research Grants: Up to USD $150,000 per year for 2 years;
Senior Research Grants: Up to USD $200,000 per year for 3 years.
| Psychosocial Research: This supports research that addresses the interrelation of behavioral, social, psychological and other quality of life factors that will benefit people living with spinal cord injury. Areas of interest include: aging, caregiving, employment, health behaviors and fitness, independent living, self-management and technology access.|
Spinal Cord Injury Research on the Translational Spectrum: This supports research to improve the understanding of traumatic spinal cord injury and develop new approaches to alleviate the dysfunction and complications that follow. The scope of this portfolio is broad, encompassing mechanistic, preclinical modeling, translational and/or clinical research.
Letter of Intent: March 3, 2021
Full Grant Application (by invitation): July 13, 2021
Spinal Cord Injury Research on the Translational Spectrum:
Letter of Intent: June 11, 2021
Full Grant Application (by invitation): November 16, 2021
|International||The Aneurysm and AVM Foundation (TAAF) Cerebrovascular Research Grant Awards||USD $25,000.||This supports scientific research projects that will significantly move the field forward toward effective understanding of the mechanisms of cerebrovascular disease as they relate to aneurysms, AVMs and complex vascular malformations. Applications in basic science, clinical care and epidemiological studies are accepted.||March 5, 2021.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Breast Cancer Research Program (BCRP)||USD $450,000-$25M (depending on the program)||The BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.|
- Breakthrough Award Levels 1 and 2
- Breakthrough Award Level 3 and Level 4
- Era of Hope Scholar Award
- Innovator Award
- Transformative Breast Cancer Consortium Award
|Breakthrough Award Levels 1 and 2
Pre-Application (Letter of Intent): March 11, 2021.
Application: March 25, 2021.
Breakthrough Award Level 3 and Breakthrough Award Level 4
Pre-Application (Preproposal): March 12, 2021.
Invited Application: June 23, 2021.
Era of Hope Scholar Award
Pre-Application (Letter of Intent): March 11, 2021.
Application: March 25, 2021.
Letters of Recommendation: March 29, 2021.
Pre-Application (Preproposal): March 11, 2021.
Invited Application: June 23, 2021.
Letters of Recommendation: June 25, 2021.
Transformative Breast Cancer Consortium Award
Pre-Application (Preproposal): March 12, 2021.
Invited Application: June 23, 2021.
|International||Pfizer Global Medical Grants (GMG): 2021 Global ANGPTL3 ASPIRE||Up to USD $250,000 for up to 3 years.||The clinical area of this request for proposals is dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). This grant supports basic science, pre-clinical research and clinical research that advances medical knowledge of the role of ANGPTL3 in health and disease.||Letter of Intent: March 12, 2021.
Full Proposal (by invitation): July 2, 2021.
|International||US FDA Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Inhalation Products (U01) Clinical Trials Optional||$USD 200,000 in total for maximum 2 years.||The purpose is to use CFD to produce verified and validated predictions of regional lung deposition for at least one currently marketed MDI or DPI in human upper and lower airways and to develop an in vitro-in vivo correlation (IVIVC) between model predictions and at least one relevant in vitro metric.||March 15, 2021.|
|International||ResMed Foundation Grants||Clinical Research Proposals: USD $250,000.|
Physician and Public Awareness Proposals: USD $10,000.
| Clinical Research Proposals: The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of sleep disordered breathing (SDB) and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. The Foundation is also interested in the application of novel screening and diagnostic tools to identify more easily SDB/OSA, as well as new and better paradigms to improve patient adherence and compliance with positive airway pressure and ventilation-based treatment methods.|
Physician and Public Awareness Proposals: To further the awareness and knowledge of the inherent dangers of untreated SDB, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.
|Clinical Research Proposals: March 15 and September 15, 2021.
Physician and Public Awareness Proposals: June 15 and December 15, 2021.
|International||CHEST Foundation 2021 Requests for Proposals||Eli Lilly and Company Distinguished Scholar in Critical Care Medicine: USD $150,000 for 3 years.|
Research Grants (Various Topics): Varies by grant from USD $10,000 to $100,000 for 1 year.
| Eli Lilly and Company Distinguished Scholar in Critical Care Medicine: Applications must address research that: (1) enhances scientific knowledge, advances evidence-based medicine, and/or improves clinical/community practice related to respiratory health patients; (2) furthers the understanding of the mechanism and management of acute and life-threatening respiratory illness; or (3) addresses the organizational attributes associated with the optimal delivery of respiratory health services. Projects must also demonstrate how it will have a positive impact on the lung health of a community.|
Research Grants (Various Topics): Support projects that will lead to breakthroughs in the treatment of chest diseases and patient care. The following grants are available: Pulmonary Hypertension; COVID-19; COVID-19 and Diversity; Nontuberculosis Mycobacteria Diseases; Critical Care; Lung Cancer; Alpha-1 Antitrypsin Deficiency; Chronic Obstructive Pulmonary Diseases; Cystic Fibrosis; Pulmonary Fibrosis; Sarcoidosis; Severe Asthma; Sleep Medicine; Medical Education; Women's Lung Health.
NOTE: Applicants to all grants must have CHEST membership at time of application.
|March 31, 2021.|
|International||Sigma Theta Tau International Honor Society of Nursing (STTI) Nursing Research Grants|| Sigma/Emergency Nurses Association Foundation Grant:Up to USD $6,000.|
Sigma/Association of Nurses in AIDS Care (ANAC) Grant:Up to USD $2,500 for 1 year.
Sigma/Chamberlain College of Nursing Education Research Grant:Up to USD $10,000 for 1 year.
Sigma/Hospice and Palliative Nurses Foundation End of Life Nursing Care Research Grant:Up to USD $10,000 for 1 year.
Sigma Global Nursing Research Grant: Up to USD $10,000 for 18 months.
|Sigma and collaborating nursing organizations present the following research grant opportunities to nurses around the globe.|
- Sigma/Emergency Nurses Association Foundation Grant: For nursing research that will advance the practice of emergency nursing.
- Sigma/Association of Nurses in AIDS Care (ANAC) Grant: This includes studies focused on HIV prevention, symptom management, promotion of self-care and adherence. Proposals for pilot and/or developmental research may be submitted for the grant.
- Sigma/Chamberlain College of Nursing Education Research Grant: Focused on excellence and innovation in nursing education. Applicant must be a member in good standing of Sigma.
-Sigma/Hospice and Palliative Nurses Foundation End of Life Nursing Care Research Grant: For the advancement of nursing care through research. Proposals for pilot and/or developmental research may be submitted
- Sigma Global Nursing Research Grant: The project should be conducted by a cross-country (at least two countries) research team and focus on responding to health disparities globally.
| Sigma/Emergency Nurses Association Foundation Grant:March 31, 2021.
Sigma/Association of Nurses in AIDS Care (ANAC) Grant:April 1, 2021.
Sigma/Chamberlain College of Nursing Education Research Grant:April 1, 2021.
Sigma/Hospice and Palliative Nurses Foundation End of Life Nursing Care Research Grant:April 1, 2021.
Sigma Global Nursing Research Grant: May 1, 2021.
|International||American Academy of Child and Adolescent Psychiatry (AACAP): Various Opportunities||USD $15,000.||- AACAP Pilot Research Award for Attention Disorders: This supports child and adolescent psychiatry fellows and early career||April 1, 2021.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Lung Cancer Research Program (LCRP)||Concept Award: Up to USD $100,000 for up to 1 year.|
Career Development Award: Up to USD $250,000 for up to 2 years.
|Concept Award: Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. Not intended to support an incremental progression of an already established research project; instead, this award mechanism is for pursuit of serendipitous observations by supporting high-risk studies that have the potential to reveal entirely new avenues for investigation.|
Career Development Award: Supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher. Supports impactful research projects with an emphasis on discovery. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. Applicant at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment.
|Pre-application (Letter of Intent): April 6, 2021.
Application: April 20, 2021.
|International||Prostate Cancer Foundation (PCF)-Pfizer Health Equity Challenge Awards||USD $100,000-$150,000 for up to 2 years.||This supports general research projects that will improve the understanding of or reduce disparities in the diagnosis, management and outcomes of prostate cancer patients in minority and underserved communities. Proposals in the following topic areas are of particular interest:|
- Identification of barriers in the delivery of equitable healthcare
- Health Services research programs to study and optimize care delivery
NOTE: The applicant team must have at least three (3) investigators, including one young investigator. The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six-years following completion of a professional degree (see above) or subsequent mentored academic or clinical training program.
|Letter of Intent: April 9, 2021.
Full Proposal (by invitation): August 30, 2021.
|International||US Department of Defence (DoD) Congressionally Directed Medical Research Program (CDMRP) FY21 Amyotrophic Lateral Sclerosis Research Program (ALSRP): Various Opportunities||- Therapeutic Development Award: Up to USD $1M for up to 3 years.|
- Therapeutic Idea Award:Up to USD $500,000 or up to $600,000 if applying for the therapeutic biomarker options. Up to 2 years.
- Clinical Development Award: Up to US
|- Therapeutic Development Award: Supports secondary preclinical validation and IND-enabling studies of therapeutics for ALS.|
- Therapeutic Idea Award: Supports hypothesis-driven preclinical therapeutic development. Projects focusing primari
|Pre-Application: April 9, 2021.
Application (by invitation): July 15, 2021.
|International||Harrington Discovery Institute (HDI) Scholar-Innovator Program: 2022 Harrington Scholar-Innovator Award||USD $100,000 for 2 years.||This grant supports all disease areas and is designed to advance promising drug discovery research towards the clinic. In addition to grant funding, HDI provides guidance and oversight in all aspects of drug development, while taking no rights to intellectual property, which is retained by the grantee/their institution. |
NOTE: An MD is required for eligibility.
|Letter of Intent (LOI): April 16, 2021.
Full Proposal (by invitation): July 26, 2021.
|International||Cancer Research UK/National Cancer Institute Cancer Grand Challenge Awards||~$40,000 for proposal development. $25 million dollars over 5 years.||This global funding platform sets ambitious challenges to inspire new thinking, providing diverse, global teams with funding to unleash their scientific creativity. Teams should be international, with no more than 70% of the activity (and funding) being based in a single country. There is no requirement for teams to be led by, or comprise team members, who are based in the UK or US. Please see details of the 9 challenges for this year's competition on the Grand Challenge website.||Expression of interest (EOI): April 22, 2021.
Full Application: October, 2021 (date TBA)
|International||Morton Cure Paralysis Fund (MCPF) Research Grant||USD $5,000 to $75,000 for 1 year.||This funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of enabling scientists to develop the proof concept data necessary to apply for larger grants. The focus areas are: |
1. Understanding the effects of spinal cord injury at the cellular level, particularly with emphasis on that which determines apoptosis and/or prohibits regrowth.
2. Studying strategies to promote neuronal growth and survival, encourage the formation of synapses, enhance the production of myelin, restore conduction capabilities, or otherwise lead to restoration of the compromised circuitry in the acutely and chronically injured CNS.
3. Evaluating new therapies in clinical trial.
|April 30, 2021; October 31, 2021.|
|International||American Academy of Pediatrics (AAP) Neonatal Resuscitation Program (NRP) 2021 Grants||NRP Human Factors or Education Grant: Up to USD $15,000 for 1 year.|
NRP Young Investigator Award:Up to USD $15,000 for 1 year.
NRP Research Grant Program: Up to USD $50,000 for 1 year.
|NRP Human Factors or Education Grant: Any health care professional with an interest in human factors impact on delivery room resuscitation or optimization of NRP education.|
NRP Young Investigator Award:Physicians-in-training or individuals within four years of completing fellowship training.
NRP Research Grant Program: Any health care professional with an interest in Neonatal Resuscitation.
|Intent to Apply: May 7, 2021.
Full Application (by invitation): August 20, 2021.
|International||Biogen: Various Opportunities||--||Biogen considers requests across a variety of disease areas including Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Biosimilars (Crohn's Disease and Rheumatoid Arthritis), Multiple Sclerosis, and Spinal Muscular Atrophy. The Biogen website lists the specific areas of interest for each opportunity below:|
- Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
- Patient Education: Supports independent educational activities for patients or caregivers.
- General Grant: Supports a project or program that does not fit any of the other defined grant categories.
|May 15, August 15, November 1.|
|International||Coalition for Epidemic Preparedness Innovations (CEPI) Calls for Proposals||Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps: Up to USD $140 million.||Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps: This is to rapidly expand access to and confidence in COVID-19 vaccines by i) generating clinical evidence in special / sub-populations / age groups or ii) addressing clinical development gaps. Clinical trials which expand access and capacity in low- and middle-income countries (LMICs) are particularly encouraged.||Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps: Expressions of Interest accepted on a rolling basis until May 28, 2021.
|International||Alzheimer's Drug Discovery Foundation (ADDF): Core Funding Programs||Up to USD $600,000 or $3,000,000.||Drug Development: This supports in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.|
Value: Up to USD $600,000 for 1 year.
Program to Accelerate Clinical Trials (PACT): This supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. Value: Up to USD $3,000,000 for multi-year projects.
Neuroimaging and CSF Biomarker: This aims to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Value: Up to USD $600,000 for 1 year.
Prevention Pipeline: This supports studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Value: Up to USD $3,000,000 for multi-year projects.
NOTE: Amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for the Drug Development or PACT RFPs.
|Letter of Intent: May 28, 2021; October 1, 2021.
Invited Full Proposal: April 16, 2021; July 30, 2021; December 3, 2021.
|International||The U.S. Agency for International Development (USAID) Global Health Broad Agency Announcement for Research and Development||Various||This Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health.||May 30, 2022|
|International||Pfizer Global Medical Grants (GMG): COVID-19 Vaccine Grants||--||COVID-19 Vaccine General Research (now open): Pfizer is accepting COVID-19 general research grant requests that address the following areas: Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.|
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations.
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.
COVID-19 Vaccine Independent Medical Education (coming soon): Optimize the prevention of COVID-19 by:
- Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
- Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer's vaccine.
COVID-19 Vaccine Population Health (coming soon): Optimize the prevention of COVID-19 by increasing the understanding and familiarity with COVID-19 and Pfizer's COVID-19 vaccine among the general population.
|Vaccine General Research: Rolling submission.
Independent Medical Education: TBA
Population Health: TBA
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Peer Reviewed Medical Research Program (PRMRP)||Clinical Trial Award: 1) Clinical trial only: funding limit not defined; up to 4 years; 2) Planning Phase with clinical trial: Up to USD $500,000 for the planning phase and up to 18 months for the planning phase.|
Discovery Award: Up to USD $200,000 for up to 2 years.
Focused Program Award: Up to USD $7.2 million for up to 4 years.
Investigator-Initiated Research Award: Up to USD $1.6 million or up to USD $2 million including a Partnering PI Option. Up to 4 years.
Technology/Therapeutic Development Award: Funding Level 1: Up to USD $2 million for up to 4 years; Funding Level 2: Up to USD $4 million for up to 4 years.
|Applications must address one or more of the potential FY21 PRMRP Topic Areas listed on the pre-announcement website. Note that the more than 40 Topic Areas have not been finalized for the pre-announcement. The following award mechanisms are anticipated:|
- Clinical Trial Award: 1) Clinical trial only 2) Planning Phase with clinical trial
- Discovery Award
- Focused Program Award
- Investigator-Initiated Research Award
- Technology/Therapeutic Development Award
|Pre-application and application deadlines TBA.|
|International||Alzheimer's Association: International Research Grant Program||--||Multiple Opportunities||Various
|International||Solving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research.||$50,000 to $500,000 USD for up to 2 years.||The TDI of SKC only supports clinical research.||Preliminary Proposal Deadline: Ongoing|
|NIH||Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)||--||National Institute of Environmental Health Sciences (NIEHS) seeks to promote rapid understanding of the potential contributions of current and past exposure to environmental agents that may exacerbate COVID-19 susceptibility, disease severity, and progression. Examples of environmental exposures relevant to the NIEHS mission include: toxic chemicals, air pollutants, second hand tobacco smoke, e-cigarette vapors, metals, and other environmental chemical exposures that may impact health outcomes. In addition, some health outcomes that are linked to environmental exposures (asthma, diabetes, and other pulmonary, cardiovascular, and metabolic diseases) are also risk factors for COVID-19.||March 1, 2021; April 1, 2021; May 3, 2021.|
|NIH||NIH Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)||--||This supports research that improves our understanding of the behavioral, social, and economic effects of the pandemic and to enhance our ability to control its spread. These effects will likely be particularly acute for NIH-designated health disparity populations , and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.||This notice applies from March 4, 2021 to May 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes||--||This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:|
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
|This notice applies to due dates on or after March 8, 2021, and subsequent receipt dates through January 7, 2024.|
|NIH||Mood Disorders in People Living with HIV: Mechanisms and Pathways|
- RFA-MH-21-116 (R01 Clinical Trial Optional)
- RFA-MH-21-117 (R21 Clinical Trial Optional)
|--||This supports studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.|
- RFA-MH-21-116 (R01 Clinical Trial Optional): Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate. Exploratory and high-risk research projects should consider applying to the companion R21 announcement RFA-MH-21-117.
- RFA-MH-21-117 (R21 Clinical Trial Optional): Exploratory and high-risk research projects are appropriate. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-MH-21-116.
|March 10, 2021.|
|NIH||Research on Current Topics in Alzheimer's Disease and Its Related Dementias |
- PAR-19-070 (R01 Clinical Trial Optional)
- PAR-19-071 (R21 Clinical Trial Not Allowed)
|--||This invites applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of notices that are linked at the top of the funding opportunity websites.||March 11, 2021; July 9, 2021; November 12, 2021.|
|NIH||NIH Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 - Clinical Trial Optional)||--||This will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of cardiovascular disease (CVD) in Type 1 Diabetes Mellitus (T1DM), and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.||March 15, 2021; October 15, 2021.|
|NIH||Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)||--||The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.||March 17, 2021; July 19, 2021; November 17, 2021; March 17, 2022; July 19, 2022; November 7, 2022|
|NIH||NIH Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)||--||This is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples.||Deadlines: April 22, 2021; November 3, 2021.|
|NIH||NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||--||National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.||This notice applies to due dates on or after May 5, 2021 and subsequent receipt dates through September 7, 2024.|
|NIH||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Research Project Grant (R01 - Clinical Trial Required)||--||This supports research in areas relevant to normal and abnormal human development, including: contraception, fertilization, pregnancy, childbirth, prenatal and postnatal development; childhood development through adolescence; intellectual and developmental disabilities; and rehabilitation medicine. This is specifically for applications that propose one or more clinical trials.||May 7, 2021 (for AIDS and AIDS-related applications)|
|NIH||Neural Regulation of Cancer|
- PAR-19-353 (R01 Clinical Trial Not Allowed)
- PAR-19-354 (R21 Clinical Trial Not Allowed)
|--||These opportunities encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.||May 27, 2021; October 21, 2021; May 27, 2022|
|NIH||NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)||--||This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.||This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through January 7, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers||--||This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.||This notice applies to due dates on or after June 5, 2021, and subsequent receipt dates through January 8, 2024.|
|NIH||Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)||--||This invites exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.||June 8, 2021; November 17, 2021|
|NIH||Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)||--||This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||June 8, 2021; November 17, 2021|
|NIH||Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)||--||This invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||June 8, 2021; November 17, 2021|
|NIH||Single-Site Investigator-Initiated Clinical Trials (R61/R33)||--||This grant supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||June 10, 2021; October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)||--||This grant supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||June 10, 2021; October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||NIH Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)||--||This encourages theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. Other outcomes of interest include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.||June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023.|
|NIH||National Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)||--||This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.||June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022|
|NIH||NIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)||--||This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.||July 14, 2021; September 7, 2021; July 14, 2022; September 7, 2022.|
|NIH||NIH Tobacco Regulatory Science (R01 Clinical Trial Optional)||--||This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).||July 14, 2021, February 15, 2022, July 14, 2022, February 14, 2023.|
|NIH||New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service|
- PAR-20-273 (R01 Clinical Trial Required)
- PAR-20-274 (R34 - Clinical Trial Optional)
|--||This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.|
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
|August 11, 2021; November 18, 2021; August 11, 2022; November 18, 2022; August 11, 2023|
|NIH||NIH High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)||--||This will support high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder (SUD)-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway). Applicants may also propose secondary screens and/or validation of high value identified targets.||September 15, 2021.|
|NIH||Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention|
- PA-18-861 (R03 - Clinical Trial Optional)
- PA-18-862 (R21 - Clinical Trial Optional)
- PA-18-863 (R01 - Clinical Trial Optional)
|--||The purpose is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.||Standard dates apply until January 8, 2022 (R03), or September 8, 2021 (R21, R01).|
|NIH||Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2||--||This NOSI encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:|
- SARS-CoV-2 candidate vaccines
- non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
- therapeutic approaches to treat COVID-19
|Applications will be accepted once a month through September 14, 2021.|
|NIH||Emotion Regulation, Aging and Mental Disorder|
- PA-19-094 (R01 Clinical Trial Not Allowed)
- PA-19-095 (R21 Clinical Trial Not Allowed)
|--||This encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Applicants with preliminary data may wish to apply using the R01 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies utilizing existing data may wish to apply using the R21 mechanism.||Standard dates apply until January 8, 2022.|
|NIH||Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)||--||This supports projects that utilize open-access data available via the Bioinformatics Resource Centers (BRCs), alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases. Projects focused on influenza, Mycobacterium tuberculosis (TB), antimicrobial resistance and malaria are encouraged although projects based on other pathogens relevant to National Institute of Allergy and Infectious Diseases will be supported.||Standard dates apply until January 8, 2022.|
|NIH||Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities||--||This seeks research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US. Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the US and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions.||This notice applies to receipt dates through January 8, 2022.|
|NIH||Bioengineering Research Grants (BRG)|
- PAR-19-158 (R01 Clinical Trial Not Allowed)
- PAR-19-159 (R01 Clincal Trial Required)
|--||The purpose is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.||Standard dates apply until January 8, 2022.|
|NIH||Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)||--||The purpose is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.||Standard dates apply until May 8, 2022.|
|NIH||NIH Dissemination and Implementation Research in Health||--||This supports innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.|
'- PAR-19-274 (R01 Clinical Trial Optional)
- PAR-19-275 (R21 Clinical Trial Optional)
-PAR-19-276 (R03 Clinical Trial Not Allowed)
|Standard dates apply until May 8, 2022.|
|NIH||Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)||--||The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.||Applications will be accepted on a rolling basis, expiring on September 1, 2022.|
|NIH||Notice of Special Interest (NOSI): Research in the Emergency Setting||--||This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.||This notice applies to receipt dates through September 8, 2022.|
|NIH||Co-infection and Cancer|
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
|--||The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.||Standard dates apply until January 8, 2023|
|NIH||Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)||--||This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.||Standard dates apply until January 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities||--||NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:|
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic||--||The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Occupational Safety and Health Research (R01) ||--||The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.||Standard dates apply until November 18, 2023.|
|NIH||NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) ||--||This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.||Standard AIDS dates apply until January 8, 2024.|
|NIH||NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) ||--||This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities.||Standard AIDS dates apply until January 8, 2024.|
|NIH||Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)||--||This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.||Standard dates apply until January 8, 2024.|
|NIH||Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders||--||National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.||This notice applies to receipt dates through January 8, 2024.|
|NIH||Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis||--||This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.||This notice applies to receipt dates through May 8, 2024.|
|NIH||Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||--||This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.||This notice applies to receipt dates through July 5, 2024.|
|NIH||Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection||--||This NOSI encourages research to understand: |
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
|This notice applies to due dates through September 8, 2024.|
|NIH||NIH Parent Announcements||--||NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)|
Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (PA-20-184)
Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (PA-20-200)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) (PA-20-195)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) (PA-20-196)
|Standard dates apply unless otherwise stated.|